<DOC>
	<DOCNO>NCT00200967</DOCNO>
	<brief_summary>The purpose trial determine whether regularly schedule use inhale long-acting beta agonist ( salmeterol ) set concomitant use inhaled corticosteroid ( beclomethasone hydroflouroalkane ( HFA ) inhaler ) detrimental effect asthma control people bear B16-Arg/Arg genotype beta-2 adrenergic receptor gene , compare people asthma similar severity bear B16-Gly/Gly genotype .</brief_summary>
	<brief_title>Asthma Clinical Research Network ( ACRN ) Trial - Long-Acting Beta Agonist Response Genotype ( LARGE )</brief_title>
	<detailed_description>BACKGROUND : The purpose study compare effect long-acting beta agonist patient asthma receive inhaled corticosteroid express two distinct polymorphism beta-2 adrenergic receptor . DESIGN NARRATIVE : Participants homozygous arginine glycine 16th amino-acid position β-2 adrenergic receptor ( B16 Arg/Arg B16 Gly/Gly ) . Individuals match opposite genotype force expiratory volume one second ( FEV1 ) race . Matched participant enter 8-week run-in period . This 62-week crossover design subject receive follow therapy : - Beclomethasone HFA ( 240 µg twice day ( BID ) ) + as-needed ( PRN ) albuterol : 8-week run-in - Beclomethasone HFA ( 240 µg BID ) + salmeterol ( 50 µg BID ) + PRN ipratropium bromide + PRN albuterol : 18-week treatment period - Beclomethasone HFA ( 240 µg BID ) + PRN albuterol : 8-week run-out - Beclomethasone HFA ( 240 µg BID ) + placebo salmeterol + PRN ipratropium bromide + PRN albuterol : 18-week treatment period - Beclomethasone HFA ( 240 µg BID ) + PRN albuterol : 10-week run-out The order treatment receive two treatment period randomize .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Male female , age 18 old Clinical history consistent asthma For subject regularly use inhaled corticosteroid , FEV1 50 % predict , methacholine PC20 FEV1 16 mg/ml 12 % 200 ml , improvement FEV1 2 puff inhale albuterol For subject regularly use inhaled corticosteroid , FEV1 40 % predict , methacholine PC20 FEV1 8 mg/ml 12 % 200 ml , improvement FEV1 2 puff inhale albuterol Genotype eligibility ( determined screening ) Smoker ( total smoking history must less 10 pack year ) Significant unstable medical condition asthma History lifethreatening asthma require treatment intubation mechanical ventilation past 10 year Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>